Physician profile
Kunwardeep Dhillon
NPI 1205215688
$2,274.27
in general payments reported to CMS, 2019-2025
25 companies · $1,027 in 2025
The $1,027 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.58 · 2022: $14.66 · 2023: $260 · 2024: $960 · 2025: $1,027.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,985 · Education: $261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,984.63 |
| Education | $261.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $535.06 | 2023-2025 | Trelegy Ellipta, Nucala |
| Jazz Pharmaceuticals INC. | $466.67 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $211.36 | 2024-2025 | Glassia |
| Harmony Biosciences LLC | $133.60 | 2024 | |
| Abbvie INC. | $114.31 | 2023-2024 | Teflaro, Avycaz, Dalvance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.10 | 2024-2025 | Ofev |
| Regeneron Healthcare Solutions, INC. | $81.19 | 2024-2025 | Dupixent |
| Baxter Healthcare | $79.80 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Inspire Medical Systems, INC. | $78.13 | 2023-2024 | Inspire |
| Astrazeneca Pharmaceuticals LP | $76.36 | 2022-2025 | Airsupra |
| Verona Pharma, INC. | $68.99 | 2025 | Ohtuvayre |
| Pulmonx Corporation | $38.93 | 2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Philips North America LLC | $34.81 | 2023-2024 | (8874) Incourage |
| Travere Therapeutics, INC. | $29.43 | 2025 | |
| Tanabe Pharma America, INC. | $28.47 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $28.29 | 2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $26.59 | 2025 | Jynarque, Voyxact |
| Resmed Corp | $22.50 | 2024 | |
| Pfizer INC. | $21.90 | 2024 | |
| Genzyme Corporation | $16.04 | 2025 | |
| United Therapeutics Corporation | $15.47 | 2025 | Tyvaso |
| Avadel Cns Pharmaceuticals, LLC | $15.01 | 2024 | Lumryz |
| Calliditas Therapeutics US INC. | $14.90 | 2025 | Tarpeyo |
| Fisher & Paykel Healthcare INC | $14.78 | 2024 | Fisher & Paykel Healthcare |
| Grifols USA, LLC | $13.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kunwardeep Dhillon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.